Objectives: Atrophic vaginitis (AV), which is common in postmenopausal women, is characterized by vaginal dryness, dyspareunia, and discomfort. There are a variety of therapeutic agents for the treatment of AV, besides hormone replacement therapy. We performed this systematic review to compare the effectiveness of various therapies for symptom improvement in AV patients. Methods: We searched the Cochrane Library, EMBASE, MEDLINE, and other literature (Google Scholar, Web of Science, and hand search) for studies published between January 2010 and March 2015. AV was evaluated by the following outcomes: vaginal pH, dyspareunia, vaginal dryness, or cytological change (endometrial thickness, percentages of superficial cells and parabasal cells). They measured treatment efficacy with various outcomes pertaining to AV symptoms. Results: Meta-analysis suggested that ospemifene was effective against dyspareunia, vaginal dryness, endometrial thickness, and percentage changes in superficial and parabasal cells. Vaginal pH was most affected by soy isoflavone vaginal gel. Ospemifene was effective for AV symptoms. 
Introduction
Atrophic vaginitis (AV) appears in approximately 45% of postmenopausal women. Symptoms of AV are dyspareunia, dryness, changed vaginal pH, and urinary and genital changes. 1 The decrease in serum estrogen level after menopause causes these symptoms. AV has potentially negative effects on quality of life and can be related to secondary diseases such as urinary tract infection.
2~4
AV is treated with hormone replacement therapy (HRT), typically estrogen. 5, 6 Estrogen therapy is sufficient to restore normal vaginal acidity and microorganisms, assists epithelial thickening, causing an increase in vaginal discharge, and helps to improve the symptoms of AV. 5 One approach to low-dose estrogen therapy is to insert estrogen or estradiol as a cream, tablet, or ring into the vagina. Systemic side effects of this therapy are possible, but the risk is insignificant. 7 Potential risks of low-dose estrogen therapy have J MM not been reported in a well-designed study. However, using this therapy for patients who form estrogen-dependent tumors, such as breast cancer survivors or patients with latent breast cancer, is controversial. 8 Recently, in addition to estrogen, there has been interest in other treatments for AV, such as selective estrogen receptor modulators (SERM) (e.g., ospemifene), tissue-selective estrogen complexes (TSEC) (e.g., bazedoxifene), estriol, and natural products (e.g., soy isoflavone, sea buckthorn oil).
SERM and TSEC, when combined with estrogen treatments, improve clinical benefits because they provide a specific estrogen receptor. Recently, some clinical trials have shown that TSEC containing bazedoxifene with estrogen treatment had effects on endometrial changes, decreased menopausal symptoms, and decelerated postmenopausal loss of bone mass. 9, 10 Estriol is a type of estrogen; tablets containing a low dose of estriol have been promoted for maturation and proliferation of the vaginal epithelial layer. A beneficial profile of the tablet has been indicated in diverse small clinical studies. 11 Natural product treatments for AV that have been studied include soy isoflavone and sea buckthorn oil. Soy isoflavone has effects like those of estrogen, and it occurs naturally in soy. 12 Sea buckthorn oil has also been studied because of associated improvement in the vaginal epithelium. 13 In other study of AV, lipofilling with platelet-rich plasma (PRP) relieved symptoms. These are show that lipofilling with PRP can be effective for vaginal atrophy.
14 A variety of therapies for AV are available, but it is hard to determine which therapies are most effective. In addition, it is need to think about the effects on AV symptoms.
This review was conducted to perform a network metaanalysis of randomized controlled trials (RCTs) to identify effective drugs for relief of AV and to identify drug efficacy on vaginal symptoms (vaginal pH, dyspareunia, vaginal dryness, and cytological change) in postmenopausal women. We did a random-effects multiple-treatments metaanalysis within a Bayesian framework; the results are summarized using effect sizes and their credible intervals (CrI).
Materials and Methods

Study eligibility criteria
The Bayesian network meta-analysis was carried out to make indirect comparisons among treatments when direct comparisons were not possible. Markov chain Monte Carlo simulation was used for the posterior distributions. Three parallel Markov chain Monte Carlo simulations were runned for a period of 10,000 iterations after the first 10,000 were deleted as the burn-in period. All the evidence was analyzed using two approaches: a consistency model and an inconsistency model. The fit of the two models was assessed using the deviance information criterion, and the model that showed lower residual deviance was selected.
We calculated the probability that each drug was the most effective (first best) drug, the second drug, the third drug, and so on; these results are presented graphically. The probability was the surface under the cumulative ranking (SUCRA) probabilities, which was expressed as percentages comparing each intervention to an imaginary intervention that is always the best without uncertainty. A SUCRA value of x percent means that the drug accomplishes x percent of the effectiveness of this imaginary drug; thus, larger SU-CRA values denote more effective interventions.
All analyses were performed using R of version 3. 
Results
For the study analysis, Fig Six articles did not contain available data, 37 were review papers, 32 were not RCTs, 9 were not relevant to the topic, 4 were not suitable because of their study period, and 2
were not suitable for quantitative synthesis in the metaanalysis. Fig. 2 for bazedoxifene 20 mg plus conjugated estrogen 0.625 mg).
Results are summarized in Fig. 3B and 4B. There appeared to be a decrease in the percentage of parabasal cells with bazedoxifene plus conjugated estrogen and ospemifene at all doses compared to placebo (not statistically significant). Bazedoxifene alone had no effect.
Vaginal pH
Network meta-analysis combining direct and indirect estimates demonstrated that soy isoflavone vaginal gel had the highest probability (34%) of being ranked as most effective drug and it produced the greatest change in vaginal pH (mean but the probability of its being ranked highest was less (27%).
Results are summarized in Fig. 3E and 4E. The intervention with sea buckthorn oil was a failure compared with placebo in terms of the improvement of vaginal dryness. 
Endometrial thickness
Discussion
This systematic review has clearly described the results of nine 12-week clinical RCTs of AV treatment drugs. It is the first study to survey the comparative treatment effects of AV therapeutic agents for six vaginal symptoms using a network meta-analysis. Several drugs were indirectly compared 
Conclusion
This study compared the effects of several therapeutic agents on symptoms of AV through a network meta-analy- 
